Search Results - combination

36 Results

Sort By:

Combinations of ASOs for the Modulation of SMN Expression in SMA Patients

Unmet NeedSpinal muscular atrophy (SMA) is a devastating neuromuscular disease that predominantly affects children and is the most common cause of hereditary infant mortality. The disease is caused by low levels of survival motor neuron (SMN) protein, due to recessive mutations in the SMN1 gene. Importantly, the copy number variation of SMN2, a homologous...

Published: 3/13/2026 | Inventor(s): Charlotte Sumner, Constantin d'Ydewalle, Frank Rigo, C. Bennett

Keywords(s): CNS and Neurological Disorders, Combination, Disease Indication, Drug Delivery Vehicle, Muscle Atrophy, Muscular Disorders, Neurodegenerative Diseases, Peptides/Prodrugs, Single, Targeted Therapy, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Neurology > Motor Neuron Diseases, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Proteins

Targeting of Myeloid-Derived Suppressor Cells (MDSCs) for Cancer Treatment

Value Proposition· Addresses key resistance mechanism: targets MDSCs, a central driver of resistance to immune checkpoint inhibitors in metastatic and poorly immunogenic cancers· Synergistic combination strategy: Combines epigenetic modulators (HDAC and DNA methyltransferase inhibitors) with anti-PD-1 and anti-CTLA-4 antibodies to restore...

Published: 3/12/2026 | Inventor(s): KiBem Kim, Bert Vogelstein, Kenneth Kinzler, Shibin Zhou

Keywords(s): Antagonists/Inhibitors, Antibodies, Biologics, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Targeted chemo-immunotherapy delivery

Value PropositionEnhanced effect of immunotherapyTreatment for recurrent or metastatic diseaseImproved glioma treatment Unmet NeedImmunotherapy represents a new paradigm in cancer treatment. Molecules that effectively reverse the immune suppressing nature of cancer have the potential to enhance the body’s ability to work systemically combat cancer (Pardoll,...

Published: 3/12/2026 | Inventor(s): Dimitrios Mathios, Betty Tyler, Drew Pardoll, Henry Brem, Michael Lim

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities

Induction of Synthetic Lethality with Epigenetic Therapy (ISLET) by Combined DNA Methyltransferase and Aurora Kinase Inhibition

Invention NoveltyThis invention is a novel paradigm for the induction of synthetic lethality through epigenetic modulations. This can induce functionality and efficacy of therapeutics against cancer cells that may have resistance to each therapeutic alone. Value PropositionThe complex and adaptive nature of the host of diseases termed cancer poses significant...

Published: 3/13/2026 | Inventor(s): Srinivasan Yegnasubramanian, William Nelson, Ajay Vaghasia, Philipp Nuhn

Keywords(s): Cancers, Chemotherapy/Targeted Therapy, Combination, Disease Indication, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities

M4N and Temozolomide Combination Therapy for Glioblastoma multiforme (GBM)

Unmet NeedGlioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults and remains one of the most aggressive types of malignancies. The mainstay of GBM treatment is surgery, radiation and adjuvant chemotherapy using temozolomide (TMZ). While treatment options have incrementally improved, survival rates remains dismal. Only...

Published: 3/13/2026 | Inventor(s): Ru Chih Huang, Jong ho Chun, Yu-Ling Lin, Yu-Chuan Liang, Kuang-Wen Liao, Tiffany Jackson, David Mold, Chien-Hsien Lai

Keywords(s): Agonists/Promoters, Brain Cancer, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Glioblastoma, Glioma, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Brain Cancer

Targeting PTPN22 in Cancer Therapy

Unmet NeedTumor-infiltrating lymphocytes (TILs) such as B-cells, T-cells, and natural killers are gaining traction in anti-tumor immune responses. TILs involve the use of special immune cells called T-cells, otherwise known as lymphocytes, which protect the body from viral infections, fight cancer, and coordinate the activities of other cells during...

Published: 3/13/2026 | Inventor(s): Elizabeth Jaffee, Won Jin Ho, Soren Charmsaz

Keywords(s): Cancers, Combination, Discovery/Research Tools, Disease Indication, In Vivo Research Tool, Knock Out Mouse Model, Mouse Model, Target, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Research Tools > Animal Models

Use of Combination Retinoic Acid and dsRNA Products for Skin Rejuvenation

Unmet NeedGlobally, the anti-aging cosmetic treatment market is projected to grow to $57.5B dollars in 2020. Currently, one of the leading the leading topical ingredients in anti-aging creams for wrinkle reduction is retinoids, which are derivatives of vitamin A. Retinoic acid, the active metabolite of retinoids, has been shown to help repair sun damaged...

Published: 3/13/2026 | Inventor(s): Luis Garza, Dongwon Kim

Keywords(s): Biologics, Chemotherapy/Immunotherapy, Combination, Disease Indication, Nucleic Acid, Skin Disorders, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Wound Healing

Category(s): Technology Classifications > Therapeutic Modalities

Leptin Prevents Opiate-induced Respiratory Depression

Description:Unmet Need The opioid epidemic continues to be a public health crisis, with about 130 Americans dying every day from an opioid overdose. Opiate-mediated respiratory suppression (ORS) is the primary cause of opiate-associated deaths, and obesity greatly increases opiate-related mortality. Obesity also contributes to obstructive sleep apnea...

Published: 3/13/2026 | Inventor(s): Vsevolod Polotsky, David Mendelowitz, Carla Freire

Keywords(s): Biologics, Combination, Drug Delivery Mechanism, Intranasal Administration, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Respiratory Diseases

Compositions and Methods for Treating Melanoma--Further Modifications

Unmet NeedTherapeutic cancer vaccines aim to activate the antitumor T cell response. These vaccines are designed to prime naïve antitumor T cells, by activating antigen presenting cells, particularly dendritic cells (DCs). DNA-based cancer vaccines are a particularly promising approach, partially due to the ease with which they can be manufactured....

Published: 3/13/2026 | Inventor(s): Richard Markham, James Gordy

Keywords(s): Biologics, Cancers, Combination, Disease Indication, Melanoma, Skin Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Vaccine

Category(s): Clinical and Disease Specializations > Oncology > Melanoma, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines

Administration of DNA Vaccines with DNA Encoding Ii-PADRE Generates Potent PADRE-specific CD4+ T-cell Immune Responses and Enhances Vaccine Potency

Unmet Need: DNA vaccine technology is a desirable antiviral and cancer immunotherapeutic strategy for its simple design and cost-effective implementation. However, current DNA vaccine programs are hindered by poor immunogenicity. Technical Details: Johns Hopkins researchers have designed a novel fusion construct to enhance immunogenicity to DNA vaccines....

Published: 3/12/2026 | Inventor(s): Chien-Fu Hung, T.c. Wu

Keywords(s): Cancers, Combination, Disease Indication, Immunotherapy/ Immunotherapy, Therapeutic Matter, Therapeutics, Therapy Type

1 2 3 4